Apnimed Locks $150M Credit Line for AD109 Sleep Apnea Launch

Apnimed locked a $150M senior secured credit facility with HealthCare Royalty Partners to fund the commercial launch of AD109, an oral pill for obstructive sleep apnea, pending FDA approval.

The structure isn’t $150M on day one. Apnimed gets $50M at closing. Another $50M drops only on FDA approval. A third $50M tranche requires hitting a pre-specified sales milestone. HCRx takes a synthetic royalty on top — a low single-digit percentage of net sales.

A four-year interest-only window, extendable to five years on a net sales milestone, keeps Apnimed’s cash burn manageable during early commercialization. HCRx isn’t betting on principal repayment. It’s pricing the royalty stream.

There’s no approved oral therapy for OSA. AD109 targets the neuromuscular root cause of upper airway collapse. Apnimed completed two Phase III trials, SynAIRgy and LunAIRo, before this raise.

If AD109 gets approved and finds commercial traction, HCRx’s royalty percentage on a large-market drug becomes a serious long-duration asset.

FDA’s decision on AD109 is pending.

Diana Kowalski